Skip to content

Consequences of suboptimal glucocorticoid replacement therapy in Addison*s disease; The metabolic syndrome and quality of life.

Consequences of suboptimal glucocorticoid replacement therapy in Addison*s disease; The metabolic syndrome and quality of life. - Consequences of suboptimal GRTin Addison*s disease

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON32767
Enrollment
242
Registered
2010-02-03
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Addison's disease primary adrenal insufficiency

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - primary adrenal insufficiency - 18-70 years - stable glucocorticoid replacement therapy (no adjustments of regime and dosage for 3 months)

Exclusion criteria

Exclusion criteria: - intercurrent infectious or serious disease for which it is necessary to increase glucocorticoid dosage - high dose inhalation glucocorticoids (>800 microgram a day) - pregnancy

Design outcomes

Primary

MeasureTime frame
1) Presence of metabolic syndrome (3 or more abnormalities of waist circumference, blood pressure, triglycerides, HDL cholesterol, glucose) 2) Quality of life score

Secondary

MeasureTime frame
Presence of glucocorticoid receptor polymorfisms and GRT in relation to the metabolic syndrome and QoL.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)